Highlights Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Delayed Canadian Securities Exchange Other stock markets 10:20:44 2024-05-13 EDT			5-day change	1st Jan Change
0.025 ^CAD	0.00%		-16.67%	-16.67%

04-23	FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	MT
04-23	Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	04-23	MT
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	04-23	MT
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	MT
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	MT
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	CI
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	04-02	MT
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	04-02	CI
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	03-27	MT
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	03-27	CI
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	03-19	MT
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	03-19	CI
Revive Therapeutics Provides Corporate Update	03-12	MT
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-28	CI
Revive Therapeutics Exploring Use of Bucillamine for Long COVID	02-01	MT
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	02-01	CI
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	01-16	CI
Revive Therapeutics Says Completed Development of a Novel Lyophilized Formulation of Bucillamine	01-10	MT
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	01-10	CI
Revive Therapeutics Collaborates with Attwill Medical Solutions to Develop Novel Lyophilized Formulation of Bucillamine	12-18	MT
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of A Novel Lyophilized Formulation of Bucillamine	12-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Revive Therapeutics Ltd.

Equities

RVV

CA7615161030

Highlights

Filters